trial

An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

NCTId NCT01939548
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 240 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2014-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
240 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2013-10
Primary completion
2014-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
PF-02545920

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

44 total
Birmingham, United StatesLittle Rock, United StatesCerritos, United StatesCulver City, United StatesEscondido, United StatesGarden Grove, United StatesOakland, United StatesOceanside, United StatesOrange, United StatesRiverside, United StatesSan Diego, United StatesSan Diego, United States

Linked catalysts

1
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In — primary completion2014-10

Facts & assertions

4 sourced
Enrollment
240
Phase
PHASE2
Primary Completion Date
2014-10
Status
TERMINATED
relationships
The graph out of here
drug
PF-02545920
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication